<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d348" origId="Carvedilol"><sentence id="DrugDDI.d348.s0" origId="s0" text="Inhibitors of CYP2D6;"><entity id="DrugDDI.d348.s0.e0" origId="s0.p1" charOffset="14-20" type="drug" text="CYP2D6"/></sentence><sentence id="DrugDDI.d348.s1" origId="s1" text="poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol ."><entity id="DrugDDI.d348.s1.e0" origId="s1.p4" charOffset="21-32" type="drug" text="debrisoquin"/><entity id="DrugDDI.d348.s1.e1" origId="s1.p7" charOffset="50-60" type="drug" text="carvedilol"/><entity id="DrugDDI.d348.s1.e2" origId="s1.p9" charOffset="87-93" type="drug" text="CYP2D6"/><entity id="DrugDDI.d348.s1.e3" origId="s1.p11" charOffset="103-112" type="drug" text="quinidine"/><entity id="DrugDDI.d348.s1.e4" origId="s1.p12" charOffset="114-124" type="drug" text="fluoxetine"/><entity id="DrugDDI.d348.s1.e5" origId="s1.p13" charOffset="126-136" type="drug" text="paroxetine"/><entity id="DrugDDI.d348.s1.e6" origId="s1.p15" charOffset="142-153" type="drug" text="propafenone"/><entity id="DrugDDI.d348.s1.e7" origId="s1.p23" charOffset="188-193" type="drug" text="drugs"/><entity id="DrugDDI.d348.s1.e8" origId="s1.p32" charOffset="249-259" type="drug" text="enantiomer"/><entity id="DrugDDI.d348.s1.e9" origId="s1.p33" charOffset="263-273" type="drug" text="carvedilol"/><pair id="DrugDDI.d348.s1.p0" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e1" interaction="?"/><pair id="DrugDDI.d348.s1.p1" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e2" interaction="?"/><pair id="DrugDDI.d348.s1.p2" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e3" interaction="?"/><pair id="DrugDDI.d348.s1.p3" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e4" interaction="?"/><pair id="DrugDDI.d348.s1.p4" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e5" interaction="?"/><pair id="DrugDDI.d348.s1.p5" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e6" interaction="?"/><pair id="DrugDDI.d348.s1.p6" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e7" interaction="?"/><pair id="DrugDDI.d348.s1.p7" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e8" interaction="?"/><pair id="DrugDDI.d348.s1.p8" e1="DrugDDI.d348.s1.e0" e2="DrugDDI.d348.s1.e9" interaction="?"/><pair id="DrugDDI.d348.s1.p9" e1="DrugDDI.d348.s1.e1" e2="DrugDDI.d348.s1.e2" interaction="?"/><pair id="DrugDDI.d348.s1.p10" e1="DrugDDI.d348.s1.e1" e2="DrugDDI.d348.s1.e3" interaction="?"/><pair id="DrugDDI.d348.s1.p11" e1="DrugDDI.d348.s1.e1" e2="DrugDDI.d348.s1.e4" interaction="?"/><pair id="DrugDDI.d348.s1.p12" e1="DrugDDI.d348.s1.e1" e2="DrugDDI.d348.s1.e5" interaction="?"/><pair id="DrugDDI.d348.s1.p13" e1="DrugDDI.d348.s1.e1" e2="DrugDDI.d348.s1.e6" interaction="?"/><pair id="DrugDDI.d348.s1.p14" e1="DrugDDI.d348.s1.e1" e2="DrugDDI.d348.s1.e7" interaction="?"/><pair id="DrugDDI.d348.s1.p15" e1="DrugDDI.d348.s1.e1" e2="DrugDDI.d348.s1.e8" interaction="?"/><pair id="DrugDDI.d348.s1.p16" e1="DrugDDI.d348.s1.e1" e2="DrugDDI.d348.s1.e9" interaction="?"/><pair id="DrugDDI.d348.s1.p17" e1="DrugDDI.d348.s1.e2" e2="DrugDDI.d348.s1.e3" interaction="?"/><pair id="DrugDDI.d348.s1.p18" e1="DrugDDI.d348.s1.e2" e2="DrugDDI.d348.s1.e4" interaction="?"/><pair id="DrugDDI.d348.s1.p19" e1="DrugDDI.d348.s1.e2" e2="DrugDDI.d348.s1.e5" interaction="?"/><pair id="DrugDDI.d348.s1.p20" e1="DrugDDI.d348.s1.e2" e2="DrugDDI.d348.s1.e6" interaction="?"/><pair id="DrugDDI.d348.s1.p21" e1="DrugDDI.d348.s1.e2" e2="DrugDDI.d348.s1.e7" interaction="?"/><pair id="DrugDDI.d348.s1.p22" e1="DrugDDI.d348.s1.e2" e2="DrugDDI.d348.s1.e8" interaction="?"/><pair id="DrugDDI.d348.s1.p23" e1="DrugDDI.d348.s1.e2" e2="DrugDDI.d348.s1.e9" interaction="?"/><pair id="DrugDDI.d348.s1.p24" e1="DrugDDI.d348.s1.e3" e2="DrugDDI.d348.s1.e4" interaction="?"/><pair id="DrugDDI.d348.s1.p25" e1="DrugDDI.d348.s1.e3" e2="DrugDDI.d348.s1.e5" interaction="?"/><pair id="DrugDDI.d348.s1.p26" e1="DrugDDI.d348.s1.e3" e2="DrugDDI.d348.s1.e6" interaction="?"/><pair id="DrugDDI.d348.s1.p27" e1="DrugDDI.d348.s1.e3" e2="DrugDDI.d348.s1.e7" interaction="?"/><pair id="DrugDDI.d348.s1.p28" e1="DrugDDI.d348.s1.e3" e2="DrugDDI.d348.s1.e8" interaction="?"/><pair id="DrugDDI.d348.s1.p29" e1="DrugDDI.d348.s1.e3" e2="DrugDDI.d348.s1.e9" interaction="?"/><pair id="DrugDDI.d348.s1.p30" e1="DrugDDI.d348.s1.e4" e2="DrugDDI.d348.s1.e5" interaction="?"/><pair id="DrugDDI.d348.s1.p31" e1="DrugDDI.d348.s1.e4" e2="DrugDDI.d348.s1.e6" interaction="?"/><pair id="DrugDDI.d348.s1.p32" e1="DrugDDI.d348.s1.e4" e2="DrugDDI.d348.s1.e7" interaction="?"/><pair id="DrugDDI.d348.s1.p33" e1="DrugDDI.d348.s1.e4" e2="DrugDDI.d348.s1.e8" interaction="?"/><pair id="DrugDDI.d348.s1.p34" e1="DrugDDI.d348.s1.e4" e2="DrugDDI.d348.s1.e9" interaction="?"/><pair id="DrugDDI.d348.s1.p35" e1="DrugDDI.d348.s1.e5" e2="DrugDDI.d348.s1.e6" interaction="?"/><pair id="DrugDDI.d348.s1.p36" e1="DrugDDI.d348.s1.e5" e2="DrugDDI.d348.s1.e7" interaction="?"/><pair id="DrugDDI.d348.s1.p37" e1="DrugDDI.d348.s1.e5" e2="DrugDDI.d348.s1.e8" interaction="?"/><pair id="DrugDDI.d348.s1.p38" e1="DrugDDI.d348.s1.e5" e2="DrugDDI.d348.s1.e9" interaction="?"/><pair id="DrugDDI.d348.s1.p39" e1="DrugDDI.d348.s1.e6" e2="DrugDDI.d348.s1.e7" interaction="?"/><pair id="DrugDDI.d348.s1.p40" e1="DrugDDI.d348.s1.e6" e2="DrugDDI.d348.s1.e8" interaction="?"/><pair id="DrugDDI.d348.s1.p41" e1="DrugDDI.d348.s1.e6" e2="DrugDDI.d348.s1.e9" interaction="?"/><pair id="DrugDDI.d348.s1.p42" e1="DrugDDI.d348.s1.e7" e2="DrugDDI.d348.s1.e8" interaction="?"/><pair id="DrugDDI.d348.s1.p43" e1="DrugDDI.d348.s1.e7" e2="DrugDDI.d348.s1.e9" interaction="?"/><pair id="DrugDDI.d348.s1.p44" e1="DrugDDI.d348.s1.e8" e2="DrugDDI.d348.s1.e9" interaction="?"/></sentence><sentence id="DrugDDI.d348.s2" origId="s2" text="Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer."><entity id="DrugDDI.d348.s2.e0" origId="s2.p51" charOffset="243-253" type="drug" text="enantiomer"/></sentence><sentence id="DrugDDI.d348.s3" origId="s3" text="Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia."><entity id="DrugDDI.d348.s3.e0" origId="s3.p60" charOffset="93-97" type="drug" text="drug"/><entity id="DrugDDI.d348.s3.e1" origId="s3.p67" charOffset="137-146" type="drug" text="reserpine"/><entity id="DrugDDI.d348.s3.e2" origId="s3.p69" charOffset="151-179" type="drug" text="monoamine oxidase inhibitors"/><pair id="DrugDDI.d348.s3.p0" e1="DrugDDI.d348.s3.e0" e2="DrugDDI.d348.s3.e1" interaction="?"/><pair id="DrugDDI.d348.s3.p1" e1="DrugDDI.d348.s3.e0" e2="DrugDDI.d348.s3.e2" interaction="?"/><pair id="DrugDDI.d348.s3.p2" e1="DrugDDI.d348.s3.e1" e2="DrugDDI.d348.s3.e2" interaction="?"/></sentence><sentence id="DrugDDI.d348.s4" origId="s4" text="Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects."><entity id="DrugDDI.d348.s4.e0" origId="s4.p79" charOffset="0-9" type="drug" text="Clonidine"/><entity id="DrugDDI.d348.s4.e1" origId="s4.p82" charOffset="41-50" type="drug" text="clonidine"/><pair id="DrugDDI.d348.s4.p0" e1="DrugDDI.d348.s4.e0" e2="DrugDDI.d348.s4.e1" interaction="?"/></sentence><sentence id="DrugDDI.d348.s5" origId="s5" text="When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first."><entity id="DrugDDI.d348.s5.e0" origId="s5.p95" charOffset="70-79" type="drug" text="clonidine"/></sentence><sentence id="DrugDDI.d348.s6" origId="s6" text="Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage."><entity id="DrugDDI.d348.s6.e0" origId="s6.p106" charOffset="0-9" type="drug" text="Clonidine"/></sentence><sentence id="DrugDDI.d348.s7" origId="s7" text="Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection."><entity id="DrugDDI.d348.s7.e0" origId="s7.p115" charOffset="0-12" type="drug" text="Cyclosporine"/><entity id="DrugDDI.d348.s7.e1" origId="s7.p118" charOffset="46-58" type="drug" text="cyclosporine"/><entity id="DrugDDI.d348.s7.e2" origId="s7.p123" charOffset="112-122" type="drug" text="carvedilol"/><pair id="DrugDDI.d348.s7.p0" e1="DrugDDI.d348.s7.e0" e2="DrugDDI.d348.s7.e1" interaction="?"/><pair id="DrugDDI.d348.s7.p1" e1="DrugDDI.d348.s7.e0" e2="DrugDDI.d348.s7.e2" interaction="?"/><pair id="DrugDDI.d348.s7.p2" e1="DrugDDI.d348.s7.e1" e2="DrugDDI.d348.s7.e2" interaction="?"/></sentence><sentence id="DrugDDI.d348.s8" origId="s8" text="In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed."><entity id="DrugDDI.d348.s8.e0" origId="s8.p130" charOffset="38-50" type="drug" text="cyclosporine"/><entity id="DrugDDI.d348.s8.e1" origId="s8.p137" charOffset="90-102" type="drug" text="cyclosporine"/><pair id="DrugDDI.d348.s8.p0" e1="DrugDDI.d348.s8.e0" e2="DrugDDI.d348.s8.e1" interaction="?"/></sentence><sentence id="DrugDDI.d348.s9" origId="s9" text="On the average for the group, the dose of cyclosporine was reduced about 20% in these patients."><entity id="DrugDDI.d348.s9.e0" origId="s9.p146" charOffset="42-54" type="drug" text="cyclosporine"/></sentence><sentence id="DrugDDI.d348.s10" origId="s10" text="Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate."><entity id="DrugDDI.d348.s10.e0" origId="s10.p158" charOffset="96-108" type="drug" text="cyclosporine"/><entity id="DrugDDI.d348.s10.e1" origId="s10.p163" charOffset="165-175" type="drug" text="carvedilol"/><entity id="DrugDDI.d348.s10.e2" origId="s10.p166" charOffset="205-217" type="drug" text="cyclosporine"/><pair id="DrugDDI.d348.s10.p0" e1="DrugDDI.d348.s10.e0" e2="DrugDDI.d348.s10.e1" interaction="?"/><pair id="DrugDDI.d348.s10.p1" e1="DrugDDI.d348.s10.e0" e2="DrugDDI.d348.s10.e2" interaction="?"/><pair id="DrugDDI.d348.s10.p2" e1="DrugDDI.d348.s10.e1" e2="DrugDDI.d348.s10.e2" interaction="?"/></sentence><sentence id="DrugDDI.d348.s11" origId="s11" text="Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly."><entity id="DrugDDI.d348.s11.e0" origId="s11.p170" charOffset="0-7" type="drug" text="Digoxin"/><entity id="DrugDDI.d348.s11.e1" origId="s11.p172" charOffset="9-16" type="drug" text="Digoxin"/><entity id="DrugDDI.d348.s11.e2" origId="s11.p177" charOffset="64-71" type="drug" text="digoxin"/><entity id="DrugDDI.d348.s11.e3" origId="s11.p179" charOffset="76-86" type="drug" text="carvedilol"/><pair id="DrugDDI.d348.s11.p0" e1="DrugDDI.d348.s11.e0" e2="DrugDDI.d348.s11.e1" interaction="?"/><pair id="DrugDDI.d348.s11.p1" e1="DrugDDI.d348.s11.e0" e2="DrugDDI.d348.s11.e2" interaction="?"/><pair id="DrugDDI.d348.s11.p2" e1="DrugDDI.d348.s11.e0" e2="DrugDDI.d348.s11.e3" interaction="?"/><pair id="DrugDDI.d348.s11.p3" e1="DrugDDI.d348.s11.e1" e2="DrugDDI.d348.s11.e2" interaction="?"/><pair id="DrugDDI.d348.s11.p4" e1="DrugDDI.d348.s11.e1" e2="DrugDDI.d348.s11.e3" interaction="?"/><pair id="DrugDDI.d348.s11.p5" e1="DrugDDI.d348.s11.e2" e2="DrugDDI.d348.s11.e3" interaction="?"/></sentence><sentence id="DrugDDI.d348.s12" origId="s12" text="Both digoxin and COREG slow AV conduction."><entity id="DrugDDI.d348.s12.e0" origId="s12.p184" charOffset="5-12" type="drug" text="digoxin"/><entity id="DrugDDI.d348.s12.e1" origId="s12.p186" charOffset="17-22" type="drug" text="COREG"/><pair id="DrugDDI.d348.s12.p0" e1="DrugDDI.d348.s12.e0" e2="DrugDDI.d348.s12.e1" interaction="?"/></sentence><sentence id="DrugDDI.d348.s13" origId="s13" text="Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG."><entity id="DrugDDI.d348.s13.e0" origId="s13.p189" charOffset="35-42" type="drug" text="digoxin"/><entity id="DrugDDI.d348.s13.e1" origId="s13.p197" charOffset="103-108" type="drug" text="COREG"/><pair id="DrugDDI.d348.s13.p0" e1="DrugDDI.d348.s13.e0" e2="DrugDDI.d348.s13.e1" interaction="?"/></sentence><sentence id="DrugDDI.d348.s14" origId="s14" text="Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%."><entity id="DrugDDI.d348.s14.e0" origId="s14.p203" charOffset="47-55" type="drug" text="Rifampin"/><entity id="DrugDDI.d348.s14.e1" origId="s14.p204" charOffset="89-99" type="drug" text="carvedilol"/><pair id="DrugDDI.d348.s14.p0" e1="DrugDDI.d348.s14.e0" e2="DrugDDI.d348.s14.e1" interaction="?"/></sentence><sentence id="DrugDDI.d348.s15" origId="s15" text="Cimetidine increased AUC by about 30% but caused no change in Cmax."><entity id="DrugDDI.d348.s15.e0" origId="s15.p206" charOffset="0-10" type="drug" text="Cimetidine"/></sentence><sentence id="DrugDDI.d348.s16" origId="s16" text="Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem."><entity id="DrugDDI.d348.s16.e0" origId="s16.p214" charOffset="0-24" type="drug" text="Calcium Channel Blockers"/><entity id="DrugDDI.d348.s16.e1" origId="s16.p226" charOffset="128-133" type="drug" text="COREG"/><entity id="DrugDDI.d348.s16.e2" origId="s16.p229" charOffset="158-167" type="drug" text="diltiazem"/><pair id="DrugDDI.d348.s16.p0" e1="DrugDDI.d348.s16.e0" e2="DrugDDI.d348.s16.e1" interaction="?"/><pair id="DrugDDI.d348.s16.p1" e1="DrugDDI.d348.s16.e0" e2="DrugDDI.d348.s16.e2" interaction="?"/><pair id="DrugDDI.d348.s16.p2" e1="DrugDDI.d348.s16.e1" e2="DrugDDI.d348.s16.e2" interaction="?"/></sentence><sentence id="DrugDDI.d348.s17" origId="s17" text="As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."><entity id="DrugDDI.d348.s17.e0" origId="s17.p234" charOffset="52-57" type="drug" text="COREG"/><entity id="DrugDDI.d348.s17.e1" origId="s17.p240" charOffset="92-116" type="drug" text="calcium channel blockers"/><entity id="DrugDDI.d348.s17.e2" origId="s17.p241" charOffset="124-133" type="drug" text="verapamil"/><entity id="DrugDDI.d348.s17.e3" origId="s17.p243" charOffset="137-146" type="drug" text="diltiazem"/><pair id="DrugDDI.d348.s17.p0" e1="DrugDDI.d348.s17.e0" e2="DrugDDI.d348.s17.e1" interaction="?"/><pair id="DrugDDI.d348.s17.p1" e1="DrugDDI.d348.s17.e0" e2="DrugDDI.d348.s17.e2" interaction="?"/><pair id="DrugDDI.d348.s17.p2" e1="DrugDDI.d348.s17.e0" e2="DrugDDI.d348.s17.e3" interaction="?"/><pair id="DrugDDI.d348.s17.p3" e1="DrugDDI.d348.s17.e1" e2="DrugDDI.d348.s17.e2" interaction="?"/><pair id="DrugDDI.d348.s17.p4" e1="DrugDDI.d348.s17.e1" e2="DrugDDI.d348.s17.e3" interaction="?"/><pair id="DrugDDI.d348.s17.p5" e1="DrugDDI.d348.s17.e2" e2="DrugDDI.d348.s17.e3" interaction="?"/></sentence><sentence id="DrugDDI.d348.s18" origId="s18" text="Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics."><entity id="DrugDDI.d348.s18.e0" origId="s18.p252" charOffset="0-7" type="drug" text="Insulin"/><entity id="DrugDDI.d348.s18.e1" origId="s18.p254" charOffset="11-29" type="drug" text="oral hypoglycemics"/><entity id="DrugDDI.d348.s18.e2" origId="s18.p261" charOffset="112-119" type="drug" text="insulin"/><entity id="DrugDDI.d348.s18.e3" origId="s18.p263" charOffset="124-142" type="drug" text="oral hypoglycemics"/><pair id="DrugDDI.d348.s18.p0" e1="DrugDDI.d348.s18.e0" e2="DrugDDI.d348.s18.e1" interaction="?"/><pair id="DrugDDI.d348.s18.p1" e1="DrugDDI.d348.s18.e0" e2="DrugDDI.d348.s18.e2" interaction="?"/><pair id="DrugDDI.d348.s18.p2" e1="DrugDDI.d348.s18.e0" e2="DrugDDI.d348.s18.e3" interaction="?"/><pair id="DrugDDI.d348.s18.p3" e1="DrugDDI.d348.s18.e1" e2="DrugDDI.d348.s18.e2" interaction="?"/><pair id="DrugDDI.d348.s18.p4" e1="DrugDDI.d348.s18.e1" e2="DrugDDI.d348.s18.e3" interaction="?"/><pair id="DrugDDI.d348.s18.p5" e1="DrugDDI.d348.s18.e2" e2="DrugDDI.d348.s18.e3" interaction="?"/></sentence><sentence id="DrugDDI.d348.s19" origId="s19" text="Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended."><entity id="DrugDDI.d348.s19.e0" origId="s19.p267" charOffset="30-37" type="drug" text="insulin"/><entity id="DrugDDI.d348.s19.e1" origId="s19.p269" charOffset="41-59" type="drug" text="oral hypoglycemics"/><pair id="DrugDDI.d348.s19.p0" e1="DrugDDI.d348.s19.e0" e2="DrugDDI.d348.s19.e1" interaction="?"/></sentence></document>